Showing 2911-2920 of 4166 results for "".
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI Surgical System for MIGS Procedureshttps://modernod.com/news/first-subjects-enrolled-in-clinical-study-to-evaluate-safety-and-efficacy-of-omni-surgical-system-for-migs-procedures/2476422/Sight Sciences announced that enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multicenter study to evaluate the safety and efficacy of the OMNI Surgical System in performing two sequential micro-invasive glaucoma surgery (MIGS) procedures—transluminal v
- Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-initiation-of-phase-2b-clinical-study-of-csf-1-for-the-treatment-of-presbyopia/2476421/Orasis Pharmaceuticals announced the initiation of a phase 2b clinical study in the United States evaluating CSF-1 for the treatment of presbyopia. The phase 2b study is a multicenter, double-masked trial in the United States enrolling 150 participants with presbyopia to evaluate the efficacy and
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- Clinical Trials Show Safety and Efficacy of Inveltys for BID Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/Kala Pharmaceuticals announced publication of two multicenter, randomized, double-masked, vehicle-controlled clinical trials of Inveltys (loteprednol etabonate ophthalmic suspension 1%) for treatment of inflammation and pain following cataract surgery. Inveltys, which utilizes AMPPLIFY D
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou
- Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Potential Avastin Biosimilarhttps://modernod.com/news/innovent-announces-two-clinical-studies-with-the-anti-vegf-monoclonal-antibody-ibi305-a-potential-avastin-biosimilar/2479615/Innovent Biologics announced that IBI305, a recombinant humanized anti-VEGF monoclonal antibody being developed as a potential biosimilar to Avastin (bevacizumab), has met predefined primary endpoints in two randomized, head to head, clinical trials comparing IBI30
- Alcon Introduces New Medical Affairs Website in North America, Expanding Support for Patient Care and Clinical Communityhttps://modernod.com/news/alcon-introduces-new-medical-affairs-website-in-north-america-expanding-support-for-patient-care-and-clinical-community/2476149/Alcon recently launched a new website, AlconScience.com, for US- and Canada-based eye care professionals and academic institutions. The new medical affairs website consolidates information about Alcon’s scientific, academic, and related activities into one portal. Visitors may download clinically
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate